Precision Cancer Drugs Are Working, But Medicare Rules and Insurance Delays Are Slowing Them Down, Doctors Say

Stanford medical professor Bryant Lin spent years building the school's Center for Asian Health Research and Education, pushing for better lung cancer screening. Two years ago he became a Stage IV patient of the disease he'd spent his career fighting.

Lin, a non-smoker, still teaches a class on lung cancer and tells his students he's hopeful, according to NPR. "I think the future is really bright, because we're creating all of these personalized, specialized precision therapeutics for lung cancer," he said. His goal isn't necessarily a cure. It's turning the disease into something chronic and manageable.

The numbers back up some of that optimism. Five-year survival across all stages of lung cancer has doubled over three decades, according to NPR. It's still only 30%. But for early, localized cancer caught before it spreads, five-year survival tops 67%, based on data from 2015 to 2021.

What Changed the Math

The shift comes from genetic testing that identifies the specific mutation driving a patient's cancer, then matches it to a drug built for that mutation, according to UCLA oncologist Jonathan Goldman. "We can pick a drug that's really been developed for that type of cancer," Goldman told NPR.

That precision cuts collateral damage too. Targeted drugs generally hit fewer healthy cells than chemotherapy, meaning fewer brutal side effects. "Survival used to be under a year, and now it's often several years and sometimes many years," Goldman said. He was principal investigator on a study published in the New England Journal of Medicine showing major reductions in cancer recurrence tied to this approach.

The Bureaucracy Problem

None of that works if testing takes too long or insurance won't cooperate. That was the message from a four-panel event hosted by the Institute for Value-Based Medicine in Seattle on July 23, 2026, according to the American Journal of Managed Care (AJMC).

Siddhartha Devarakonda of Providence Swedish Cancer Institute, speaking on a panel moderated by Rafael Santana-Davila, said lung cancer physicians live in fear of missing a driver alteration like EGFR or ALK because catching it changes the entire first-line treatment plan. Get the sequencing wrong, and giving a patient immunotherapy before a targeted tyrosine kinase inhibitor can actively harm them, panelists said, according to AJMC.

The problem: testing takes time, and government and insurer rules don't always accommodate that. AJMC reported that Medicare's 14-day rule, along with payer mandates dictating where care happens, can delay genomic testing, redirect infusions to different facilities, and fragment monitoring for treatment side effects. Doctors on the panel described routing around this with outpatient test-ordering workarounds and pushing for institution-level policy fixes rather than waiting on payers to change course.

When a Medicare billing rule was written to prevent duplicate lab charges around hospital discharge, it wasn't designed with same-day precision oncology sequencing in mind. The result, according to the doctors quoted by AJMC, is a rule built for one era of medicine slowing down a completely different one.

Beyond Lung Cancer

The Seattle panels covered more than lung cancer. CAR T-cell therapy and bispecific antibodies are reshaping lymphoma treatment, but AJMC reported that centralized delivery requirements, the logistics of bridging patients to treatment, and anticipated monitoring rules for solid tumors are straining capacity and complicating who gets referred where.

In leukemia care, financial toxicity showed up as a recurring theme. AJMC reported high copays for venetoclax, formulary exclusions, and payment-model incentives that push doctors toward shuffling patients between outpatient and inpatient settings, sometimes favoring fixed-duration drug regimens over indefinite BTK-inhibitor therapy, not necessarily for medical reasons but for reimbursement ones.

Melanoma care faces its own version of the problem, with referral mis-triage, imaging bottlenecks and insurance-driven splitting of care fragmenting treatment. AJMC also reported that a newer diagnostic tool, CP-GEP (Merlin), failed to bring node-positivity rates for sentinel lymph node biopsy below 5%, meaning doctors are still leaning on older clinical nomograms rather than the new test.

What's Unresolved

None of the doctors quoted by AJMC or NPR called for scrapping Medicare's testing rules outright, and no federal review of the 14-day rule's interaction with genomic testing has been announced. The fixes discussed at the Seattle event were mostly institutional workarounds, not policy changes. Whether Medicare or private insurers revisit these rules as targeted cancer therapies become more common, and whether venetoclax and similar drugs see broader formulary coverage, remains an open question with no timeline attached.